全文获取类型
收费全文 | 1422篇 |
免费 | 112篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 76篇 |
妇产科学 | 17篇 |
基础医学 | 150篇 |
口腔科学 | 33篇 |
临床医学 | 211篇 |
内科学 | 294篇 |
皮肤病学 | 14篇 |
神经病学 | 49篇 |
特种医学 | 299篇 |
外科学 | 98篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 94篇 |
眼科学 | 18篇 |
药学 | 63篇 |
中国医学 | 5篇 |
肿瘤学 | 43篇 |
出版年
2023年 | 8篇 |
2021年 | 14篇 |
2020年 | 8篇 |
2019年 | 13篇 |
2018年 | 31篇 |
2017年 | 21篇 |
2016年 | 24篇 |
2015年 | 27篇 |
2014年 | 29篇 |
2013年 | 33篇 |
2012年 | 39篇 |
2011年 | 36篇 |
2010年 | 46篇 |
2009年 | 66篇 |
2008年 | 40篇 |
2007年 | 33篇 |
2006年 | 27篇 |
2005年 | 17篇 |
2004年 | 20篇 |
2003年 | 26篇 |
2002年 | 23篇 |
2001年 | 22篇 |
2000年 | 16篇 |
1999年 | 26篇 |
1998年 | 51篇 |
1997年 | 52篇 |
1996年 | 70篇 |
1995年 | 54篇 |
1994年 | 45篇 |
1993年 | 49篇 |
1992年 | 25篇 |
1991年 | 24篇 |
1990年 | 27篇 |
1989年 | 54篇 |
1988年 | 44篇 |
1987年 | 53篇 |
1986年 | 50篇 |
1985年 | 43篇 |
1984年 | 35篇 |
1983年 | 27篇 |
1982年 | 29篇 |
1981年 | 16篇 |
1980年 | 13篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 21篇 |
1976年 | 14篇 |
1975年 | 16篇 |
1971年 | 11篇 |
1970年 | 7篇 |
排序方式: 共有1541条查询结果,搜索用时 328 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
V B Van Hasselt L A Sisson S R Aach 《Journal of behavior therapy and experimental psychiatry》1987,18(3):275-283
A training program was implemented to modify a mother's behavior management skills to improve compliance in her 4-year-old child who suffered from severe developmental and physical disabilities. A multiple baseline analysis indicated that behavioral intervention was effective in training the mother to make definitive commands, provide appropriate positive attention, and persist with commands during social interactions with her child. In addition, substantial improvement in the child's compliance with mother's commands followed introduction of parent training. Further, positive collateral effects included the child's increased time on-task and decreased oppositional behavior. All gains were maintained at a 6-month follow-up probe. 相似文献
3.
4.
5.
6.
7.
8.
M D Gross B Shapiro J C Sisson A Zweifler 《Journal of endocrinological investigation》1987,10(4):359-364
To assess adrenal medulla activity in states of hyperfunction, a single 0.3 mg oral dose of clonidine hydrochloride (Catapres) was given to twelve patients with varying evidence of familial adrenal medullary hyperplasia and pheochromocytomas from kindreds with Multiple Endocrine Neoplasia type 2 syndrome (MEN-2), seven patients with sporadic pheochromocytomas and six normal subjects. Mean arterial blood pressure and plasma norepinephrine (NE) levels were lower than baseline values 2 h after clonidine in the normal subjects. Plasma epinephrine (E) rose in one normal but fell in the remainder after clonidine administration. In sporadic pheochromocytoma patients, E fell slightly in 4 and NE fell in 3 while mean arterial blood pressure was not significantly lower than baseline values in 7 patients 2 h after clonidine. In MEN-2, mean arterial blood pressure fell and there was a variable response of plasma E and NE to clonidine, which appears to be related to the presence of detectable anatomic (CT scan) and functional (131I-mlBG scintigraphy) abnormalities of the adrenal medulla. These findings are thus compatible with the spectrum of adrenal medulla dysfunction and the presumed development of pheochromocytoma in this syndrome. 相似文献
9.
10.